News Outlets Examine Issues Surrounding Ebola Treatment Research, Vaccine Development, Case Detection

News outlets discuss issues surrounding the research and development of Ebola treatments and vaccines, as well as the challenges of case detection.

Agence France-Presse: Use of placebos in Ebola drug trials unethical: experts
“Health experts from around the globe said Friday it would be unethical in drug trials to give non-active placebos to people infected with the killer Ebola virus…” (10/10).

Agence France-Presse: Three Russian Ebola vaccines ready within six months: Moscow
“Russia expects to produce three Ebola vaccines within the next six months, Health Minister Veronika Skvortsova said on Saturday…” (10/11).

Los Angeles Times: Ebola research: Fever not a surefire sign of infection
“For public health workers screening more than 1,000 air travelers who arrive each week in the United States from Ebola-stricken West Africa, one symptom above all others is supposed to signal danger: fever. So long as an individual’s temperature does not exceed 101.5 degrees and there are no visible symptoms of Ebola, health authorities say it should be assumed the person is not infectious. Yet the largest study of the current outbreak found that in nearly 13 percent of ‘confirmed and probable’ cases in Liberia, Sierra Leone, Guinea, and elsewhere, those infected did not have fevers…” (Willman, 10/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.